EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Clinical trial NCT06923761 · RECRUITING

Trial details

NCT number: NCT06923761
Sponsor: Grey Wolf Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Malignancy

Start date: 2023-05-21
Primary completion: 2027-04-30
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.